The People Behind the Shots: LGBTQ+ Contributions to Vaccine Science and Public Health

Science does not happen automatically or in a vacuum. Every vaccine that has ever protected a child from measles, every X-ray that caught a hidden infection, every drug trial that moved faster because patients demanded it... All of those advances have human beings behind them. Some of those human beings were gay, lesbian, bisexual, or transgender, and their identities are part of their stories, whether history records them or not.

This post is about some of those people.

A Transgender Pioneer Who Led the Charge Against Tuberculosis

Long before anyone was talking about representation in medicine, a physician named was quietly saving lives by convincing the state of Idaho — and later Connecticut — that the chest X-ray (a technique that uses radiation to create images of the inside of the body) was the best available tool for finding tuberculosis (TB, a serious bacterial infection that attacks the lungs) before it spread.

Hart, born in 1890, was . When he had the surgery in 1917, such procedures were extraordinarily rare and deeply stigmatized. He spent the following decades practicing medicine, researching disease, and building public health programs. He developed a specialty in — the use of X-ray technology in medicine — and recognized something that many of his colleagues had not yet accepted: that TB could be identified in a patient’s lungs via X-ray screening before that patient showed any symptoms. Finding the disease early meant treating it early, and treating it early meant fewer deaths.

Hart did not merely theorize. He built mobile screening clinics, led mass X-ray programs across Connecticut, lectured physicians and the public on TB prevention, and documented how the infection traveled through the bloodstream to attack organs beyond the lungs. His work predated many of the epidemiological tools (methods for tracking and understanding disease patterns in populations) that would later become standard practice by roughly two decades. 

The credits his research with saving countless lives. He worked as a physician, a public health officer, and a novelist, telling stories about identity and belonging during a century when both were dangerous to claim openly.

Hart died in 1962. For most of the twentieth century, histories of tuberculosis medicine did not mention his name. He is now recognized both as a medical pioneer and as one of the first documented transgender people in the United States to live openly in his affirmed gender.

The Movement That Rewrote Medical Research

The emergence of the AIDS crisis began in the summer of 1981, when medical officials observed a troubling trend: previously healthy young gay men in New York and Los Angeles . This prompted an urgent investigation by the CDC, eventually leading to the identification of HIV (human immunodeficiency virus). This virus causes AIDS (acquired immunodeficiency syndrome), a state where the immune system is sufficiently compromised to permit fatal infections.

The official response was, for a long time, far too slow. Experimental drugs were stuck in approval pipelines designed for a different era. Clinical trials (studies that test whether a medicine works in people) excluded many of the patients who most needed the treatments. People were dying while waiting for paperwork.

In 1987, the AIDS Coalition to Unleash Power (ACT UP) . The organization distinguished itself not merely through its loud and strategic protests, but through its members’ commitment to scientific literacy. By teaching themselves the intricacies of clinical trial protocols and pharmaceutical research, they identified the specific bureaucratic hurdles that prevented rapid access to treatment. Armed with this knowledge, ACT UP members presented the Food and Drug Administration (FDA), the National Institutes of Health (NIH), and various pharmaceutical firms with documented, actionable proposals to streamline these processes.

In October 1988, more than 1,000 ACT UP demonstrators in Rockville, Maryland. Within a week, the FDA issued a new rule promising faster approval of HIV and AIDS drugs. That was not a coincidence. The protesters had arrived with a concrete agenda, including demands for more diverse patient groups in clinical trials, mandatory insurance coverage for experimental treatments, and an end to trials that gave dying patients a placebo (an inactive substance used as a comparison in studies) instead of an experimental drug.

From there, did something that had never been done before in the history of medicine: a wrote what became the first comprehensive AIDS research agenda by any organization — government, academic, or otherwise — and presented it at the Fifth International Conference on AIDS in Montreal in 1989. The agenda demanded that people with AIDS be full partners in designing and running research trials. Based largely on guidelines ACT UP proposed, the FDA and the NIH approved the first "Parallel Track" program, which allowed doctors to prescribe experimental HIV drugs to patients who could not join formal clinical trials while those trials were still running.

This was a transformation in how medical research itself works. Before ACT UP, the idea that patients — especially patients from stigmatized communities — should have a seat at the table where research decisions are made was not standard thinking. After ACT UP, it became the foundation of modern community-based participatory research (a method where the people most affected by a disease are active partners in studying and fighting it).

The Activists Who Became Scientists

Two of the most enduring figures to emerge from that era were and . They are both gay men who joined ACT UP as activists and, years later, are now scientists.

Staley was a bond trader on Wall Street when he tested HIV-positive in the mid-1980s. He quit his job and joined ACT UP’s Treatment and Data Committee, eventually helping to found the in January 1992 alongside more than a dozen cofounders. TAG broke away from ACT UP with a specific mission: full-time focus on accelerating AIDS treatment research. TAG members did not just advocate for science. They learned it deeply enough to co-author research agendas, critique trial designs, and sit on NIH committees as genuine scientific partners. Staley later co-founded PrEP4All, an organization dedicated to expanding access to (pre-exposure prophylaxis, a daily or injectable medication that prevents HIV infection in people who are HIV-negative). His decades of work sit at the intersection of activism, public health, and vaccine science.

Gonsalves began his work with ACT UP in 1989 and was a . He later returned to school, earned a PhD from Yale, and is now an Associate Professor of Epidemiology at the Yale School of Public Health, a faculty member at Yale Law School, and a recipient of a MacArthur “genius” fellowship. His research focuses on mathematical modeling of infectious diseases (using equations and computer simulations to predict how diseases spread and how interventions might stop them) and health equity. In an interview with UNAIDS, he described his path as a direct continuation of what he began in ACT UP: demanding that science serve the people most harmed by disease, not just those with the fewest barriers to access.

The structural change these activists helped create — — put community members on every ACTG committee, including the executive committee. For the first time in the history of large-scale U.S. clinical research, the people most affected by a disease had formal standing to shape how that disease was studied. That model has since influenced how clinical trials across many diseases are designed.

Mark Harrington and the Art of Scientific Advocacy

is another gay man who emerged from ACT UP’s Treatment and Data Committee and helped co-found TAG in 1992. A writer and researcher by training, Harrington became one of the most effective scientific advocates in the history of HIV research. He and his colleagues produced TAG reports that were directly influential in the development of HIV protease inhibitors (a class of drugs that block a specific enzyme the virus needs to replicate, and which became the backbone of the combination therapy that turned HIV from a death sentence into a manageable chronic condition).

Harrington has worked on AIDS and tuberculosis advocacy for decades, and he has been recognized with for his contributions. (No, .) His career illustrates something that the history of vaccine and drug development often leaves out: that pushing scientists to ask different questions, design better trials, and listen to affected communities is itself a form of scientific contribution. It is not separate from science. It is part of the science.

What Happens When Research Listens to Patients

It is worth pausing on what the gay community’s involvement in HIV research actually produced, because the effects extend far beyond HIV.

Before ACT UP, the FDA approval process for drugs was slower, more rigid, and less responsive to the urgency of epidemic disease. The “Parallel Track” program that ACT UP helped establish has influenced how the FDA now handles emergency drug access. The concept of accelerated approval — allowing new drugs to be approved based on strong early evidence rather than waiting years for long-term outcome data — was built in large part on the framework that ACT UP demanded. The (which allows terminally ill patients to access experimental treatments outside of clinical trials) traces its philosophical roots to the same arguments ACT UP made at the FDA in 1988.

Researchers and public health scholars have written about how AIDS activists "radically rewrote the rules of biomedical research," as one analysis in Prospect Magazine put it. They demonstrated that science conducted in isolation from the communities it is meant to serve produces slower results, and that embedding affected communities in the research process produces better science. That lesson has shaped how researchers now approach clinical trial design across infectious diseases, cancer, and chronic illness.

Visibility in Science, Then and Now

The contributions described above are not the full picture, by the way. They are a selection of well-documented examples. LGBTQ+ people have been present across the history of medicine and public health in ways that records have not always captured, both because of deliberate erasure and because many people had to conceal their identities to survive professionally.

, a transgender neuroscientist at Stanford University who died in 2017, became in 2013 the first openly transgender scientist inducted into the National Academy of Sciences. His primary research was in neuroscience, not vaccines — he studied the role of glial cells (a type of supporting brain cell that makes up roughly 90% of the cells in the human brain) — but his visibility and his outspoken advocacy for diversity in STEM (science, technology, engineering, and mathematics) cleared a path for LGBTQ+ scientists who came after him. He spoke and wrote openly about his experiences as a transgender person in academic science, including discrimination he had faced, and challenged his colleagues to confront the barriers that kept talented people out of research.

Today, the organization maintains a public, searchable database of LGBTQ+ people working in science, with more than 2,000 entries and growing. The organization exists because visibility matters not just for the scientists who see themselves reflected in those profiles, but for the research itself. A scientific community that draws on a wider range of perspectives and experiences is, evidence suggests, a more creative and effective one.

A Note on Why This History Matters

The contributions described in this post happened despite, not because of, the conditions those scientists and advocates faced. Alan Hart built a groundbreaking medical career while hiding his identity by relocating multiple times. ACT UP members pushed past grief, their own declining health, and the open hostility of a government that moved slowly while their friends died. Gregg Gonsalves became an epidemiologist in his forties after decades of unpaid advocacy work that shaped the very field he later formally entered.

Tracking how diseases spread, designing trials that actually reflect the populations most at risk, demanding that public health systems respond with urgency to the people dying... These are not peripheral concerns in vaccine science. These issues and the people they affect are at its center. And the history of LGBTQ+ contributions to public health is, in large part, a history of people insisting that medicine do exactly that.